Optimi Health Corp.
OPTH
Positions held
Your positionsOPTH isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $23.39M | Enterprise value | $15.46M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 1.83 | Beta | 1.58 | Dividend yield | 0.00% |
| Revenue growth | -28.6% | Earnings growth | — | Gross margin | -1.8% | Operating margin | -9.6% |
| Profit margin | 0.0% | ROE | -54.4% | ROA | -16.1% | Debt / equity | 0.29 |
| Current ratio | 1.73 | Free cash flow | -$1.73M | Analyst recommendation | none | Mean target | — |
| 52w high | $6.40 | 52w low | $4.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | $0.0M | -$0.1M | $0.2M | — |
| Op margin | -1522.6% | -1363.7% | — | 2603.9% | -406.2% | — |
| Net income | -$2.4M | -$1.6M | -$1.6M | -$1.3M | -$0.9M | — |
| Gross margin | 47.5% | 89.9% | — | 725.0% | 92.6% | — |
| Gross profit | $0.1M | $0.1M | $0.0M | -$0.5M | $0.2M | — |
| Operating income | -$2.1M | -$1.4M | -$1.3M | -$1.7M | -$0.8M | — |
- Revenue +41% vs prior quarter ($0.1M vs $0.1M).
- Gross margin 47.5% (was 89.9% prior quarter).
- Operating margin compressed to -1522.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.4M | $0.4M | $0.2M | $0.1M |
| Op margin | -1081.9% | -1438.8% | -2911.5% | -9155.2% |
| Net income | -$3.7M | -$6.0M | -$5.2M | -$7.4M |
| Gross margin | -16.0% | 69.5% | 110.6% | 66.8% |
| Gross profit | -$0.1M | $0.3M | $0.2M | $0.1M |
| Operating income | -$4.6M | -$5.6M | -$5.3M | -$7.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Optimi Health to Present at the ThinkEquity Conference
2026-09-29 · Optimi Health Appoints Melanie Pump to Board of Directors
2026-09-23 · Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial
2026-09-23 · Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
2026-09-22 · Optimi Health Appoints Dr Michael Blough to Head Clinical Development
2026-09-22 · Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
2026-09-21 · Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-09-19 · Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
2026-09-17 · These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
2026-09-16 · Optimi Health to Start Phase 3 MDMA Trial Targeting PTSD in Frontline Workers
2026-09-16 · 3 Small Cap Stocks With Strong Revenue Growth And Low Debt
Price (daily)
Full chart · RSI · MACD · patterns